Search

Addressing diabetes-related complications in Tanzania and Eswatini: A comprehensive approach to eye and foot screening

Diabetes is rising globally, particularly in low- to middle-income countries (LMICs), where healthcare systems are under resourced [1,2]. Among its complications, diabetic retinopathy (DR) and diabetic foot disease are preventable yet frequently overlooked [3-6]. These problems often develop together due...

Designing ophthalmology services Part 3: How do we address the queues post‑COVID-19?

Part 1 of this series available herePart 2 of this series available here There is going to be enormous demand on ophthalmology services as they start to welcome patients back. The authors explain how modelling can help make the most...

Advances in cataract surgery

This article covers recent clinical findings in mydriasis and anaesthesia for cataract surgery, shared by Sathish Srinivasan and Keith Davey at a surgical meeting in Manchester. Towards dropless cataract surgery Day case cataract surgery is the standard of care in...

Pituitary tumours: why are they so often missed?

Part 1: Introduction, historical background and Edinburgh connections (see also Part 2 and Part 3) Is there any ophthalmologist who has not missed a pituitary tumour? Hopefully this article will help those currently in practice to avoid such an embarrassment,...

Surgical options for the treatment of hyperopia

The modern refractive surgeon has a variety of options available to treat patients with hyperopia who wish to be independent of spectacles and contact lenses. Unlike in low myopia where presbyopic patients may have the ability to see well for...

Novel changes during COVID-19 – transforming a walk-in Eye Casualty to a telephone triage service

With the current pandemic climate due to COVID-19, out of the norm approaches have been adopted in different hospitals across the UK to ensure patient safety. At our Eye Casualty (EC) department at Northampton General Hospital (NGH), we felt the...

Regulatory drug evaluations and expedited review initiatives: EU and US perspectives

The European Medicines Agency (EMA) and United States Food and Drug Administration (FDA) each conduct independent assessments of benefit-risk profile when evaluating applications to market new or modified medicines, and their respective decision-making is guided by distinct legislation, procedures and...